Evidence map›Paper›PMID 41684638›Full record

ArticleAesthetic surgery journal. Open forum2026

Mapping the UK Aesthetic Medicine Industry: Practitioner Profiles, Pricing, and Socioeconomic Gradients in Botulinum Toxin Practice.

Alexander Zargaran, David Zargaran, Hamid Reza Khademi Mansour, Lara Turan, Giulia Bocciardi, Yichen Liu, Anita Golash, Kian Daneshi, Ali Pirayesh, Alex Woollard and 1 more

Abstract read
In one paragraph

Article in Aesthetic surgery journal. Open forum, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors.

Alexander Zargaran
Hamid Reza Khademi Mansour
Lara Turan
Giulia Bocciardi
Yichen Liu
Anita Golash
Ali Pirayesh
Alex Woollard
Afshin Mosahebi

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Background: The United Kingdom aesthetic botulinum toxin industry operates with limited regulatory oversight despite being a prescription-only medication. Following recent public scrutiny, regulatory reforms are imminent, warranting comprehensive analysis to inform evidence-based policy. Objectives: The aim of the study was to characterize practitioner profiles, pricing patterns, premises types, and socioeconomic gradients in the provision of aesthetic botulinum toxin across the United Kingdom. Methods: Cross-sectional analysis was conducted of practitioners administering aesthetic botulinum toxin and fillers across the UK (January-July 2025). Data were collected from publicly available websites and social media platforms. Geographic analysis used deprivation indices to examine socioeconomic patterns. Statistical methods included descriptive analysis, χ Results: A total of 19,701 practitioners across 5589 clinics were identified, representing a 437% increase over 2 years. Doctors comprised 28.4% of practitioners, while the proportion of nonmedical aestheticians doubled from 12% to 24.8%. Practitioner density showed a 6.7-fold increase from the least (9.4 per 100,000) to the most deprived areas (63.2 per 100,000). Doctor representation declined from 34.4% in affluent areas to 27.0% in deprived areas, while odds of nonclinical botulinum toxin administering beauty salon exposure peaked in moderately deprived areas (odds ratio [OR] = 2.18). Specialist access (dermatologists/plastic surgeons) declined significantly in Quintiles 3 to 5 (ORs 0.70-0.77). Regression analysis identified practitioner profession as the strongest pricing determinant: doctors charged 32% to 38% more than aestheticians, dentists 28% to 33% more, and nurses 2% to 4% more (all Conclusions: The UK aesthetic medicine market has expanded rapidly, with significant differences in practitioner qualifications and treatment settings across socioeconomic groups. These findings provide key evidence to guide upcoming regulatory reforms and highlight the need for stronger safety oversight of prescription-only aesthetic procedures. Level of Evidence 5 Therapeutic:

Identifiers

PMID41684638
PMCPMC12892226

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.